The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report
Appendix C
Workshop Agenda and Participant List
November 1-2, 2005
Keck Center of the National Academies
500 Fifth Street, N.W. • Washington, D.C.
AGENDA
Tuesday, November 1, 2005
8:00 a.m.
Continental Breakfast
8:30 a.m.
Committee orientation (closed session)
9:00 a.m.
Workshop convocation and introductions −
Samuel Katz, chairman
9:30 a.m.
Polio eradication plan update
Looking ahead to the end-game: Bruce Aylward
Strategies for the OPV cessation era: Roland Sutter
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole. Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 69
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report
Appendix C
Workshop Agenda and Participant List
November 1-2, 2005
Keck Center of the National Academies
500 Fifth Street, N.W. • Washington, D.C.
AGENDA
Tuesday, November 1, 2005
8:00 a.m.
Continental Breakfast
8:30 a.m.
Committee orientation (closed session)
9:00 a.m.
Workshop convocation and introductions −
Samuel Katz, chairman
9:30 a.m.
Polio eradication plan update
Looking ahead to the end-game: Bruce Aylward
Strategies for the OPV cessation era: Roland Sutter
Potential roles for an antiviral: Mark Pallansch
10:15 a.m.
Overview of poliovirus biology and pathogenesis
Eckard Wimmer
OCR for page 70
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report
10:45 a.m.
Coffee Break
11:00 a.m.
Introduction to potential targets
Mutagenesis and RNAi: Raul Andino
Capsid-binding compounds: Marc Collett
Exploiting dominant inhibition: Karla Kirkegaard
Protease inhibitors: Amy Patick
12:00 p.m.
Organization of afternoon breakout sessions
12:30 p.m.
Buffet Lunch
1:30 p.m.
Breakout sessions
3:30 p.m.
Coffee Break
3:45 p.m.
Reports on breakout sessions and discussion
5:30 p.m.
Adjourn
Wednesday, November 2, 2005
8:00 a.m.
Continental Breakfast
8:30 a.m.
Organization of day 2 breakout groups
9:00 a.m.
Working breakout group discussions
1. Public Health group: How would the drug be used in eradication? Who would patients be, how would they be identified and reached? What would be the advantages and disadvantages of the potential compounds identified in day 1 for different aspects of eradication?
2. Biology group: Evaluate each of the potential antivirals: how difficult would each be to develop, how likely to elicit resistance, how long would it take to develop, what would be its possible safety issues?
3. Development group: How much would each type of antiviral cost to develop? How hard might it be to move them
OCR for page 71
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report
through the approval process? Who might develop them? What are the likely timelines involved for each? What are possible sources of funding?
10:30 a.m.
Coffee Break
10:45 a.m.
Report from breakout group 1 and discussion
11:30 p.m.
Report from breakout group 2 and discussion
12:15 p.m.
Lunch
1:15 p.m.
Report from breakout group 3 and discussion
2:00 p.m.
Wrap-up: Designing and filling in a decision matrix for each compound
4:00 p.m.
Adjourn
PARTICIPANT LIST
Jim Alexander, CDC
Bruce Aylward, WHO
Debra Birnkrant, Center for Drug Evaluation and Research, FDA
Craig Cameron, Pennsylvania State University
Marc Collett, ViroDefense, Inc.
Walter Dowdle, The Task Force for Child Survival and Development
Ellie Ehrenfeld, NIAID, NIH
Diane Griffin, Johns Hopkins Bloomberg School of Public Health
Matthias Gromeier, Duke University Medical Center
Neal Halsey, Johns Hopkins Bloomberg School of Public Health
Stephen Hughes, National Cancer Institute
Kristin Kenyan, CDC
Karla Kirkegaard, Stanford University School of Medicine
Mauricio Landaverde, Pan American Health Organization
Catherine Laughlin, NIAID, NIH
Mark McKinlay, Gentara Corporation
Philip Minor, National Institute for Biological Standards and Control, UK
OCR for page 72
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report
Akhter Molla, Abbott Laboratories
Mark Pallansch, CDC
Amy Patick, Pfizer
Olve Peersen, Colorado State University
Jane Seward, CDC
Tim Skern, Medical University of Vienna
Roland Sutter, WHO
Kimberly Thompson, Harvard School of Public Health
Linda Venczel, CDC
Margie Watkins, CDC
Jerry Winkelstein, Johns Hopkins Children’s Center
Peter Wright, Vanderbilt University School of Medicine
Staff from the National Academies Board on Life Sciences
Ann Reid, Study Director
Anne Jurkowski, Program Assistant
Fran Sharples, Director, Board on Life Sciences
Items in cart [0]
